AstraZeneca listed as one of the world's Top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage
AstraZeneca ranked 34th in Corporate Knights’ 14th annual Global 100 list of the most sustainable companies in the world
AstraZeneca identified as “biggest achiever” alongside Bank of America, and Coca Cola Enterprises Inc. (now Coca Cola European Partners) for 300% increase in renewable electricity in a single year
AstraZeneca has been recognised for its commitment to sustainability with two new, global accolades: the company has been listed as one of the 100 most sustainable companies in the world by Corporate Knights, the Toronto-based media and investment advisory firm, and has been commended for its use of renewable energy, as one of 122 multinational businesses who have made the RE100 commitment, by The Climate Group, an international non-profit organisation focused on accelerating climate action.
Katarina Ageborg, Executive Vice President for Sustainability and Chief Compliance Officer, said: “AstraZeneca aims to improve public health by not only bringing innovative science to patients with new medicines, but also through our commitment to growing sustainably, which is embedded in our business goals. We are proud to be recognised by these two leading, independent organisations for our work to broaden access to healthcare, to minimise the environmental footprint of our products and processes, and to ensure that ethics and transparency underpin everything we do.”
Corporate Knights Global 100 Index
The Global 100 Index is a ranking of the world's most sustainable companies across all sectors. The latest iteration of the index was announced at the World Economic Forum in Davos, Switzerland, today. AstraZeneca is ranked 34th globally, placing it in the top 2% of companies for sustainability performance, and ranked third among all UK companies.
The Global 100 uses a quantitative methodology to determine inclusion in the ranking, assessing factors including energy productivity, innovation capacity, safety performance and leadership diversity. All publicly traded companies with revenues greater than $1 billion are automatically considered. Each organisation is evaluated on a set of up to 17 indicators relative to their industry peers using publicly-available information. The Global 100 companies come from 22 countries and encompass all sectors of the economy.
The Climate Group
A new report released today in Davos by The Climate Group, ‘Approaching the tipping point: how corporate users are redefining global electricity markets’, tracks progress made in 2016-2017 by companies committed to 100% renewable power and provides insight into emerging trends in corporate sourcing of renewables around the world. It describes AstraZeneca as one of the “biggest achievers in 2016,” increasing its share of renewable electricity more than three-fold.
AstraZeneca’s sustainability strategy aligns to the globally-recognised UN Sustainable Development Goals. It focuses on sustainable health and recognises the interconnectivity of healthy people, a healthy environment and an ethical approach to business operations. By making science accessible, AstraZeneca can achieve its bold aspiration of helping transform the lives of 200 million patients around the world. By prioritising Access to Healthcare, Environmental Protection and Ethics and Transparency, AstraZeneca is committed to operating in a way that creates a positive impact on the world through a science-based approach to drive continuous improvement across the value chain.
Read more about Sustainability at AstraZeneca: https://www.astrazeneca.com/sustainability.html
– ENDS –
NOTES TO EDITORS
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
|Esra Erkal-Paler||UK/Global||+44 203 749 5638|
|Karen Birmingham||UK/Global||+44 203 749 5634|
|Rob Skelding||UK/Global||+44 203 749 5821|
|Matt Kent||UK/Global||+44 203 749 5906|
|Gonzalo Viña||UK/Global||+44 203 749 5916|
|Jacob Lund||Sweden||+46 8 553 260 20|
|Michele Meixell||US||+1 302 885 2677|
|Thomas Kudsk Larsen||+44 203 749 5712|
|Craig Marks||Finance, Fixed Income, M&A||+44 7881 615 764|
|Henry Wheeler||Oncology||+44 203 749 5797|
|Mitchell Chan||Oncology; Other||+1 240 477 3771|
|Christer Gruvris||Brilinta; Diabetes||+44 203 749 5711|
|Nick Stone||Respiratory; Renal||+44 203 749 5716|
|US toll free||+1 866 381 7277|